Home › Christiana Care, NovellusDx Ink Licensing Deal for Gene-Editing Tech

Christiana Care, NovellusDx Ink Licensing Deal for Gene-Editing Tech

Jul 20, 2017

NEW YORK (GenomeWeb) – Christiana Care announced today that its Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute has licensed gene-editing technology to Israeli personalized medicine firm NovellusDx as part of an ongoing cancer research collaboration.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  2. Singlera Genomics Presents Data on Cell-Free DNA Methylation Test for Early Cancer Detection

    Premium

  3. DiaSorin Receives CE Mark for Simplexa Group B Strep Assay

  4. Medicare to Cover Castle Bio’s Cutaneous Melanoma Test

  5. Co-Diagnostics Receives CE-IVD Marking for Zika Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.